Founded by Professor Moshe Szyf at McGill University in 2016, HKG Epitherapeutics Ltd. is dedicated to harness the untapped power of epigenetics in molecular diagnostics. The company is launching three novel proprietary non-invasive tests targeting healthy individuals, including epiLiver for early risk assessment of liver cancer, epiCervix for early risk assessment of cervical cancer and epiAging for measuring biological age. All of the tests target consumers in Hong Kong, Asia and the global market.
The company has invested in its expansion and built a new testing facility at HKSTP to comply with Clinical Laboratory Improvement Amendments (CLIA), College of American Pathologists (CAP) and International Organisation for Standardisation (ISO) certification requirements. The expansion will create 10 new jobs including senior lab technicians, medical laboratory technologists (MLT), automation experts, quality control and regulatory affairs professionals.
HKG Epitherapeutics has initiated a new round of fundraising to further expand its research and development, global marketing and test services to be headquartered in Hong Kong.
